Following extensive trials and seed production research, an F1 hybrid of Artemisia annua, called Hyb8001r was selected for commercial production and sales. Hyb8001r is suitable for all Artemisia growing regions, has good artemisinin concentrations and establishes good biomass quickly in the field. Hyb8001r has been registered in China.
All seed sales are conducted by Michael McDaniel at EWS. Prices are market competitive and buyers should contact Michael for a discussion. Seed samples may be available dependent on your requirements.
All hybrid seed batches undergo rigorous quality control processes to ensure they have at least 80% germination rates, 98% seed purity and over 90% genetic purity.
In the event that seed has a germination rate of 70-79%, seed will be over-packed to ensure that an acceptable number of seeds within each packet germinate successfully.
Note about seed sales for anti-malarials:
We support the World Health Organisation’s advice on the treatment of malaria (a link to their position statement of this matter can be found here). Therefore, we are only able to supply A. annua seeds to growers who supply the high quality ACT supply chain. We will not supply seeds to growers who produce teas or other forms of treatments which are not WHO approved.
If you purchase seeds, you will be supplied with a Materials Transfer Agreement with the shipping paperwork – this is to ensure that all recipients are aware of the commitment to use artemisinin in accordance with WHO recommendations.
Seed supply for other products:
If you require seed for other purposes, such as studying the secondary metabolism of A. annua to investigate other bioactive molecules, we may be able to assist you: please email Caroline Calvert for advice. If we can provide seed, this will be supplied via EWS Ltd and a charge may be levied to cover their costs of production and distribution.
The medicinal plant, Artemisia annua produces artemisinin; a vital ingredient for artemisinin combination therapy (ACT) - the World Health Organisation’s recommended treatment for malaria. With funding from the Bill & Melinda Gates Foundation, the Centre for Novel Agricultural Products (CNAP) at the University of York, conducted a comprehensive research and breeding programme on Artemisia annua. Our focus was fundamental research which could be rapidly translated into a product for Artemisia growers world-wide.
In 2010, the research led to publication of the first genetic map of Artemisia in Science1. In the same issue, a commentary on the research, published as a Perspective, stated ‘results are innovative in terms of the scale of the research and sophistication of the technologies’ (Milhous and Weina).
This world-class research provided tools to convert A. annua into a robust crop using marker-assisted breeding, vastly reducing the timelines for plant breeding. The new hybrid varieties emerging from the research programme were field trialled in many of the world’s commercial growing regions.
1. Graham, I.A. et al. (2010). Science 327: 328-331.
In 2011, CNAP signed a partnership agreement with East-West Seed International to secure sustainable, large-scale seed production and distribution of our Artemisia annua F1 hybrids. East-West Seed were the first to demonstrate field-based hybrid seed production, making the costs far more accessible to the farmers who grow Artemisia for the Artemisinin Combination Therapy supply chain.
All seed sales are conducted by Michael McDaniel at East-West Seed.
Mr Michael McDaniel
Product Market Combination Manager
Tel: +66 (0) 2831-7788
Fax +66 (0) 2923-7794
Mobile: +66 (0) 89-926-8794
For further information regarding the CNAP Artemisia Research Project, please contact Caroline Calvert.
Tel: +44 (0) 1904 328763
Department of Biology
University of York